{"disease":{"id":"alpha-1-antitrypsin-deficiency","name":"alpha 1 antitrypsin deficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT04157049","title":"Alpha-1 Research Registry","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Alpha-1 Foundation","has_results":false},{"nct_id":"NCT04180319","title":"EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT00571272","title":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)","phase":"","overall_status":"SUSPENDED","enrollment_count":1675,"lead_sponsor_name":"Arbor Research Collaborative for Health","has_results":false},{"nct_id":"NCT07152834","title":"Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction","phase":"","overall_status":"RECRUITING","enrollment_count":734,"lead_sponsor_name":"Muğla Sıtkı Koçman University","has_results":false},{"nct_id":"NCT06512454","title":"A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05178277","title":"Czech AATD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Thomayer University Hospital","has_results":false},{"nct_id":"NCT07326592","title":"Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":270,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT01851642","title":"Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs","phase":"","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT05897424","title":"Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":185,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05677971","title":"Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00313144","title":"Aralast alpha1-proteinase Inhibitor Surveillance Study","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05579431","title":"A Phase 1, First-in-human Study of VX-634","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT05727800","title":"A Phase 1, First-in-human Study of VX-668","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT05856331","title":"Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03636347","title":"A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Mereo BioPharma","has_results":false},{"nct_id":"NCT04966221","title":"Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT03679598","title":"Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT07242079","title":"Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University of Parma","has_results":false},{"nct_id":"NCT06165341","title":"Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04167345","title":"Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":true},{"nct_id":"NCT06186492","title":"A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Wave Life Sciences Ltd.","has_results":true},{"nct_id":"NCT03362242","title":"Study of ARO-AAT in Normal Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":false},{"nct_id":"NCT04474197","title":"Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":true},{"nct_id":"NCT03039335","title":"The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency","phase":"","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Biocerna LLC","has_results":false},{"nct_id":"NCT03945292","title":"Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":true},{"nct_id":"NCT00161707","title":"Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT02525861","title":"GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03767829","title":"A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03815396","title":"Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Inhibrx Biosciences, Inc","has_results":false},{"nct_id":"NCT05899673","title":"An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01651351","title":"GLASSIA Infusion Rate Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03802357","title":"Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Schön Klinik Berchtesgadener Land","has_results":false},{"nct_id":"NCT04174118","title":"Study of DCR-A1AT in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT03285100","title":"The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Canisius-Wilhelmina Hospital","has_results":false},{"nct_id":"NCT03114020","title":"Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Gerard Turino","has_results":false},{"nct_id":"NCT00242385","title":"Pharmacokinetic Study of ARALAST (Human Alpha1- PI)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT00396006","title":"Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT04722887","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Grifols Therapeutics LLC","has_results":false},{"nct_id":"NCT04764448","title":"A Study of Belcesiran in Patients With AATLD","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":true},{"nct_id":"NCT03946449","title":"Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":true},{"nct_id":"NCT06996756","title":"Gene Therapy for Alpha 1- Antitrypsin Deficiency","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT00157092","title":"Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT04262284","title":"Respreeza® Self-administration and Learning Program (AmAREtTI Study)","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT05643495","title":"A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":true},{"nct_id":"NCT02722304","title":"Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03804021","title":"Long-Term Follow-up Study of ADVM-043","phase":"","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":true},{"nct_id":"NCT02168686","title":"Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":true},{"nct_id":"NCT02870309","title":"Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Grifols Therapeutics LLC","has_results":true},{"nct_id":"NCT02870348","title":"Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Grifols Therapeutics LLC","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}